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Abstract 
This paper presents a study into the use of wearable technologies by pregnant women with Type one diabetes (T1D). 
The World Health Organisation estimates the incidence of T1D globally to be more than 422 million. Wearable tech-
nologies can potentially improve decisions around self-management by providing regular feedback on physiological 
processes. Informed decisions and choices to support self-management of this condition during pregnancy, ultimately 
enhance pregnancy outcomes. The wearable technologies under consideration include the FreeStyle LibreTM interstitial 
glucose monitor, Fitbit activity tracker, and blood pressure monitoring for home use. In addition to these devices partic-
ipants in this research area will be required to maintain a food diary. Physical activity (PA) is recommended during 
pregnancy to maintain normal blood pressure (BP), physical health and as a preventative measure against deep venous 
thromboembolism (DVT). Self-reporting of food intake is known to be problematic and is often underestimated. To fa-
cilitate assessment of portion sizes participants will be asked to use mobile phone cameras to visually record the type 
and quantity of food eaten. The collated data will be processed via statistical analysis and computational analysis before 
providing feedback using machine learning algorithms to inform decisions around the need for insulin or carbohydrate 
to maintain euglycaemia. 
 
 
1 Introduction 
T1D is an auto-immune condition caused by the destruc-
tion of pancreatic β-cells, affecting more than 422 million 
people globally [1] and impacting pregnancy outcomes 
[2].  For those living with the condition, regular insulin 
administration is required for survival [3]. The term ‘self-
management’ encompasses the necessary individual ac-
tions performed daily to identify issues and problem-solve, 
either independently or with the advice of the medical 
team, to treat and manage an individual’s health. This 
may be done independently or in partnership with 
healthcare professionals (HCPs) [4]. 
Approximately 100,000 people in Northern Ireland are 
known to have diabetes, 10,000 of whom have T1D [5]. 
T1D affects 1% of all pregnancies in Northern Ireland an-
nually, approximately 85 pregnancies and births. These 
pregnancies are high risk for mothers and foetuses as 
shown in (Figure 1). Pre-eclampsia, foetal malformation 
and mortality rates within this population are 2-5 times 
greater than for non-diabetic populations [2].  
The development and use of wearable technologies have 
improved pregnancy outcomes, particularly maternal gly-
caemic control [6][7][8]. 
A review of the literature has identified limited stud-
ies investigating the use of wearable technologies, includ-
ing intermittent glucose monitors (IGM), for participation 
in regular physical activity (PA) to reduce blood pressure, 
glycaemic variability, and maternal weight gain within 
this population [6][7]. The influence of IGM on PA and 
dietary intake on the cardio-vascular health of pregnant 
women with T1D using multiple daily injections [6] is an 
area requiring further research.  
Pregnancy guidelines recommend PA as an intervention 
to reduce the risks of venous thromboembolism and pre-
eclampsia [7]. The physiology of T1D impacts rates of 
success on safely maintaining optimal glucose levels 
when combining food, exercise and insulin therapy [6], 
[7].  Activity levels also impact blood glucose levels in 
various ways. As a result, pregnant women with T1D 
have concerns around PA and hypoglycaemia [7].  
The aim of this research is to investigate the effectiveness 
of wearable technologies and computational approaches 
in supporting pregnant women with T1D to achieve opti-
mal PA and euglycaemia with the intention of reducing 
incidences of maternal pre-eclampsia and neonatal hyper-
insulinaemia. This will be achieved through an analysis of 
heart rate and blood pressure data from activity trackers 
against IGM data and user inputs of insulin and carbohy-
drate values.  (Figure 2). 
Figure 1 Risks in pregnancies complicated by T1D. 
 
Figure 2 Schematic of intended project design. 
 
Previous studies have explored activity levels, dietary in-
take and glycaemic variations using closed loop systems 
[8] but there is a gap in research around the use of IGM 
and PA by women using multiple daily injections (MDI) 
[9]. The development of a software integration model 
combining data including carbohydrate intake, active in-
sulin, activity levels and heart-rate patterns using machine 
learning to identify patterns in glucose monitoring csv 
files for ambulatory glucose profiles (AGP) and heart rate 
patterns within FitBit csv files, for required insulin pre-
dictions could potentially be formulated using boundaries 
within the datasets generated. Decision trees, using a se-
ries of ‘if-then’ statements, could provide a means of re-
ducing the risk of disabling hypoglycaemia or hypergly-
caemia for the user [10][11][12]. The development of 
such software would be beneficial to pregnant women, 
and others, with diabetes in providing individually tai-
lored information and support with lifestyle choices to 
facilitate glucose management [12].  
2 Wearable Technology 
Wearable technologies have an important role in support-
ing recognised healthy behaviours pertinent to people 
with T1D, particularly in benefitting cardiovascular health 
whilst minimising the potential harm of glycaemic varia-
bility caused by PA [7][8][10].  
The developments within wearable technologies have 
seen an upsurge in user interest and willingness to access 
these devices which has been increasingly initiated, rec-
ognised, and promoted by HCPs [13]. Technology is a 
significant adjunct to insulin in managing diabetes and 
facilitating healthy lifestyle behaviours [9][10] (Figure 3). 
Continuous glucose monitors (CGM) and IGM have 
shown reduced variability in ambulatory glucose profiles 
of pregnant women with T1D [8][14]. Monitors display-
ing real-time glucose profiles, with trend arrows identify-
ing increases or reductions in glucose levels, ‘smart’ glu-
cometers using automated bolus calculators advising users 
of insulin doses required to maintain euglycaemia, home 
monitoring devices for blood pressure observation, activi-
ty trackers recording step counts and heart rate patterns 
alongside active minutes per day, which integrate with 
smartphones to display the information recorded by these 
devices are, for most people, easily accessible and easy to 
use [15][16].  
Figure 3 shows some of the technology available includ-
ing glucose monitors, insulin pens and pump technologies 
which record the date and time of doses administered, and 
fitness trackers which record HR, active minutes, distanc-
es walked or run and calorie output. The information from, 
for example, Fitbit devices can be accessed from the 
Cloud and stored as a csv file for further interpretation or 
investigation [17]. Blood pressure monitoring systems 
which integrate with smartphones, using Bluetooth con-
nectivity, also have the capacity for data storage in the 
Cloud and access for analysis by the user [18]. 
One of the technologies selected for this study is the 
FreeStyle LibreTM intermittent glucose sensor. This con-
sists of a microneedle filament attached to a base unit 
which is worn on the upper arm for 14 days. Interstitial 
fluid glucose readings are recorded every minute in 
Memory Bank A with one reading from every 15 minutes 
of wear recorded in Memory Bank B. The datasets gener-
ated can be downloaded and stored as csv files. They 
were added to the British National Formulary as a pre-
scription item in November 2017 and are now available to 
approximately 60% of people with T1D in Northern Ire-
land. According to Open Source Data (Figure 4), 4,763 
prescriptions for the FreeStyle LibreTM sensors were is-
sued across the 5 Health and Social Care Trusts in April 
2019. This equates to an approximate 60% uptake of this 
technology across the province. 
 
Figure 3 Currently available technology hardware 
 
Figure 4 FreeStyle LibreTM prescriptions in Northern Ire-
land from Open Source Data, courtesy of Nick Cahm 
3 Data Collection and Analysis 
As previously stated, daily variations in blood glucose 
patterns are affected by multiple factors including activity 
levels, hydration, illness, quality of sleep and hormones, 
notably placental hormones in the case of pregnant wom-
en with TID, in addition to the more widely known chal-
lenges of carbohydrate and fat intake. Woldergay et al 
classify the challenges as being of a ‘normal cause varia-
tion’ or a ‘special cause variation’ [10]. They have identi-
fied the development and use of machine learning algo-
rithms for analysing self-collected data produced by users 
of wearable technologies as an area for further develop-
ment [10]. They also identify the considerable inter-
person differences resulting from those special cause var-
iations as challenges to maintaining euglycaemia, that is 
to say no formula will produce universal results 
[10].  Cappon et al report that the increased support from 
technology in presenting visual displays of data impacts 
positively on user awareness of glucose management [9]. 
Choudary et al. [11] and Zhu [12] have shown that using 
algorithms such as Hidden Markov Model (HMM), 
Gaussian process regression models or naïve Bayes, col-
lected data can be analysed to identify individual patterns 
and trends in glucose control during and after physical 
activity to inform future self-management of glucose lev-
els.  Zhu has previously used a HMM to detect anomalies 
in historical glucose datasets [12]. She acknowledges the 
potential for incorporating additional physiological da-
tasets including heart rate and blood pressure to detect and 
predict anomalies into a HMM framework designed for 
this purpose. She proposes the expansion of observational 
symbol space to include additional data sets for 
the detection of anomalies in glucose readings 
[12]. Decision trees, incorporating ‘if-then’ statements, 
could reduce the risk of disabling hypoglycaemia by in-
creasing user awareness of this potential from individual-
ised data sets. This would minimise the need for addition-
al glucose intake by informing decisions around bolus in-
sulin doses when planned increases in BP and heart rate 
are accounted for, minimise the potential distress [11]. 
Such a model would benefit pregnant women with T1D 
by facilitating euglycaemia through the provision of indi-
vidually tailored information, minimising their risk of hy-
poglycaemia and increasing cardiac health. The proposed 
data collection and analysis framework is illustrated in 
Figure 5. 
4 Data Integration 
An integrative software application, combining data from 
IGM and activity trackers could inform decisions about 
food and PA while supporting healthy choices (Figure 
6).  The physiology of pregnancy is recognised as a natu-
rally diabetogenic state [19] with significant hormonal 
changes initiated by the placenta disrupting the action of 
insulin and elevating blood glucose levels from the sec-
ond trimester onwards [19]. Newbern and Freemark iden-
tify those hormones disruptive to insulin sensitivity and 
efficacy as being leptin, placental growth hormone (GH-V) 
and human placental lactogen (hPL) [20]. GH-V increases 
maternal insulin resistance, even in non-diabetic pregnan-
cy [20]. The proposed research has a specific application 
to T1D pregnancy which has an inherent additional bur-
den of GH-V influence, but measurement of this is be-
yond the scope of this study.   
The knowledge gathered from wearables could be com-
bined to inform choices around activity, foods eaten and 
insulin doses to be administered, further facilitating self-
management [21]. Combining the factors of impact of ac-
tivity levels and heart rate patterns, carbohydrate intake 
and glucose levels may provide insight into the duration 
of pregnancy length, the birthweights of babies born to 
these mothers and their increased risk of hypoglycaemia 
and jaundice in the first 24 hours after the birth. 
 
 
Figure 5 Schematic of proposed data collection and anal-
ysis framework. 
 
 
 
 Figure 6 Preliminary diagram of intended visual 
representation showing combined glucose and HR trends. 
5 Summary 
Blood glucose predictions, whether they be calculated 
manually or computationally using algorithms, are based 
on current blood glucose levels, carbohydrate intake and 
physiological factors, including hormones and exercise 
[16]. Access to wearable technology improves glucose 
control [9], specifically time in target range throughout 
pregnancy [6]. The concomitant changes to insulin re-
quirements are qualified by feedback provided from mon-
itors and routine capillary glucose samples. There is a 
significant volume of data generated from IGM, the use of 
activity & heart rate trackers, and also from capillary glu-
cose monitors. A software system combining the infor-
mation from IGM, heart rate trackers, BP monitors, food 
logs etc. into a single platform would provide enhanced 
information on the impact of these variables and glucose 
variability [22]. This could provide integrated care and 
healthier lifestyle choices within this pregnant population. 
Reducing anxiety around exercise induced hypoglycaemia 
has the potential to reduce the higher than average inci-
dences of Pre-eclampsia and of optimising neonatal out-
comes through the use of an integrative data analysis 
framework. 
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